A lot of
people
from poor nations do not have enough money to pay for the
medicine
that can cure their
diseases
.
While
some may argue that pharmaceutical
companies
should offer discounts to these poor
people
so that they can access
treatment
, I do not believe
this
can remedy the situation because these
drug
companies
should run their
businessFix the agreement mistake
show examples
instead
of sharing the responsibility to ensure
drug
accessibility to everyone.
In addition
,
people
will still have the financial burden often
due to
prolonged
treatment
courses.Reduced price level generates lower revenue, which can push down the research and development spending by the pharmaceutical
companies
, resulting in fewer drugs reaching the market and eventually exacerbating
drug
scarcity.
In other words
, offering a lower
drug
cost to residents of less affluent countries will not reduce their death rate from curable
diseases
because it is not the business of pharmaceutical
companies
to ensure
people
can obtain their
medicine
, but
Instead
, they should always prioritise earning money by selling their products, so that they can invest in
further
research and develop more effective
drug
products.
For example
, Pfizer has a lot of HIV drugs that can save
people
's lives, but the company do not reduce their product prices for the Cambodians, as they need to maintain their business revenue.
In addition
, reducing
drug
prices can never be a viable measure to curb poor
people
’s death from curable
diseases
because the scenario includes, but is not limited to, inadequate local healthcare infrastructures that break the supply chain hampering the delivery of medicines on time to millions of
people
.
Also
, there are many chronic
diseases
that require the use of life-long
medicine
, and
drug
discounts cannot offset the burden
due to
long
treatment
costs.
For example
, a slight decrease in the
drug
price for many inflammatory
diseases
,
such
as rheumatic arthritis, does not bring a huge impact
toChange preposition
show examples
the
overall
drug
costs for the patient that will rely on the
medicine
indefinitely.
To conclude
, I do not believe pharmaceutical
companies
should offer their products to poor
people
at lower costs because it will lower their revenue and spending on research, which will impact their
overall
production.
Furthermore
,
drug
price cuts cannot reduce the mortality rate significantly as patients may still need to pay a lot
due to
long
treatment
durations for some perennial
diseases
.